Coexpression cluster:C782
From FANTOM5_SSTAR
Full id: C782_B_Burkitt_lymphoma_splenic_acute_CD19_xeroderma
Phase1 CAGE Peaks
| Hg19::chr10:49880649..49880677,+ | p@chr10:49880649..49880677 + |
| Hg19::chr12:54446974..54447007,+ | p@chr12:54446974..54447007 + |
| Hg19::chr19:39108743..39108750,- | p5@MAP4K1 |
| Hg19::chr2:65159543..65159557,- | p2@LOC400958 |
| Hg19::chr2:65159562..65159594,- | p1@LOC400958 |
| Hg19::chr2:65159616..65159630,- | p4@LOC400958 |
| Hg19::chr2:65159651..65159662,- | p5@LOC400958 |
| Hg19::chr2:65159748..65159759,- | p3@LOC400958 |
| Hg19::chr5:85961934..85961944,+ | p@chr5:85961934..85961944 + |
| Hg19::chr6:6587579..6587601,- | p3@LY86-AS1 |
Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data
No results for this coexpression
Enriched Gene Ontology terms on this co-expression cluster<b>Summary:</b> Results for GOStat analysis on co-expressed clusters. Each cluster with promoters mapping to at least two different genes was analysed with GOStat (PMID: 14962934) with default parameter. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br>data
| GO ID | GO name | FDR corrected p-value |
|---|---|---|
| GO:0008349 | MAP kinase kinase kinase kinase activity | 0.00120687625103026 |
| GO:0045610 | regulation of hemocyte differentiation | 0.00120687625103026 |
| GO:0000185 | activation of MAPKKK activity | 0.00402292083676753 |
| GO:0042386 | hemocyte differentiation | 0.00402292083676753 |
| GO:0018209 | peptidyl-serine modification | 0.00402292083676753 |
| GO:0018105 | peptidyl-serine phosphorylation | 0.00402292083676753 |
| GO:0007257 | activation of JNK activity | 0.00670486806127922 |
| GO:0043507 | positive regulation of JNK activity | 0.00670486806127922 |
| GO:0043506 | regulation of JNK activity | 0.00670486806127922 |
| GO:0000187 | activation of MAPK activity | 0.0120687625103026 |
| GO:0007254 | JNK cascade | 0.0120687625103026 |
| GO:0043406 | positive regulation of MAP kinase activity | 0.0120687625103026 |
| GO:0031098 | stress-activated protein kinase signaling pathway | 0.0120687625103026 |
| GO:0032147 | activation of protein kinase activity | 0.0120687625103026 |
| GO:0004702 | receptor signaling protein serine/threonine kinase activity | 0.012390596177244 |
| GO:0043405 | regulation of MAP kinase activity | 0.0140299364182268 |
| GO:0018193 | peptidyl-amino acid modification | 0.0164574034231399 |
| GO:0045860 | positive regulation of protein kinase activity | 0.0164574034231399 |
| GO:0045595 | regulation of cell differentiation | 0.0164574034231399 |
| GO:0033674 | positive regulation of kinase activity | 0.0164574034231399 |
| GO:0051347 | positive regulation of transferase activity | 0.0164574034231399 |
| GO:0000165 | MAPKKK cascade | 0.0164574034231399 |
| GO:0030097 | hemopoiesis | 0.0168962675144236 |
| GO:0048534 | hemopoietic or lymphoid organ development | 0.0168962675144236 |
| GO:0005057 | receptor signaling protein activity | 0.0168962675144236 |
| GO:0002520 | immune system development | 0.0168962675144236 |
| GO:0050793 | regulation of developmental process | 0.0198732289336316 |
| GO:0045859 | regulation of protein kinase activity | 0.0198732289336316 |
| GO:0043549 | regulation of kinase activity | 0.0198732289336316 |
| GO:0051338 | regulation of transferase activity | 0.0198732289336316 |
| GO:0043085 | positive regulation of catalytic activity | 0.0199329238879836 |
| GO:0007243 | protein kinase cascade | 0.0283615918992111 |
| GO:0005083 | small GTPase regulator activity | 0.0345971191962008 |
| GO:0050790 | regulation of catalytic activity | 0.0429505959925475 |
| GO:0065009 | regulation of a molecular function | 0.0456655878768206 |
| GO:0004674 | protein serine/threonine kinase activity | 0.0456655878768206 |
| GO:0030695 | GTPase regulator activity | 0.0456655878768206 |
Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br>uberon_data<br>disease_data<br>
| Ontology term | p-value | n |
|---|---|---|
| lymphocyte of B lineage | 1.14e-109 | 24 |
| pro-B cell | 1.14e-109 | 24 |
| B cell | 3.80e-61 | 14 |
| lymphocyte | 3.03e-52 | 53 |
| common lymphoid progenitor | 3.03e-52 | 53 |
| nucleate cell | 3.50e-50 | 55 |
| lymphoid lineage restricted progenitor cell | 2.53e-48 | 52 |
| nongranular leukocyte | 7.25e-26 | 115 |
| hematopoietic lineage restricted progenitor cell | 2.61e-22 | 120 |
| leukocyte | 3.72e-21 | 136 |
| hematopoietic oligopotent progenitor cell | 3.87e-17 | 161 |
| hematopoietic multipotent progenitor cell | 3.87e-17 | 161 |
| hematopoietic stem cell | 3.17e-16 | 168 |
| angioblastic mesenchymal cell | 3.17e-16 | 168 |
| hematopoietic cell | 3.70e-15 | 177 |
| mature B cell | 3.18e-13 | 2 |
| pre-B-II cell | 3.18e-13 | 2 |
| transitional stage B cell | 3.18e-13 | 2 |
| small pre-B-II cell | 3.18e-13 | 2 |
| immature B cell | 3.18e-13 | 2 |
| precursor B cell | 4.15e-09 | 3 |
| antibody secreting cell | 1.42e-07 | 1 |
| plasma cell | 1.42e-07 | 1 |
| plasmablast | 1.42e-07 | 1 |
| B-1 B cell | 2.50e-07 | 1 |
| Ontology term | p-value | n |
|---|---|---|
| spleen | 1.06e-18 | 3 |
| gastrointestinal system mesentery | 1.06e-18 | 3 |
| stomach region | 1.06e-18 | 3 |
| mesentery | 1.06e-18 | 3 |
| gastrointestinal system serosa | 1.06e-18 | 3 |
| mesentery of stomach | 1.06e-18 | 3 |
| gut mesentery | 1.06e-18 | 3 |
| dorsal mesentery | 1.06e-18 | 3 |
| dorsal mesogastrium | 1.06e-18 | 3 |
| peritoneal cavity | 1.06e-18 | 3 |
| spleen primordium | 1.06e-18 | 3 |
| hemopoietic organ | 8.10e-14 | 7 |
| immune organ | 8.10e-14 | 7 |
| vermiform appendix | 2.35e-07 | 1 |
| caecum | 2.35e-07 | 1 |
| midgut | 2.35e-07 | 1 |
| stomach | 2.51e-07 | 8 |
| food storage organ | 2.51e-07 | 8 |
| tonsil | 2.66e-07 | 1 |
| mucosa-associated lymphoid tissue | 2.66e-07 | 1 |
| lymphoid tissue | 2.66e-07 | 1 |
| tonsillar ring | 2.66e-07 | 1 |
| Ontology term | p-value | n |
|---|---|---|
| lymphoma | 7.25e-22 | 10 |
| acute leukemia | 1.10e-07 | 1 |
| lymphatic system cancer | 2.50e-07 | 1 |
| lymphosarcoma | 2.50e-07 | 1 |
| genetic disease | 2.83e-07 | 1 |
| monogenic disease | 2.83e-07 | 1 |
| xeroderma pigmentosum | 2.83e-07 | 1 |
| anemia | 3.62e-07 | 1 |
Overrepresented TFBS (DNA) motifs on this co-expression cluster<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data
Novel motifs
JASPAR motifs
| Motifs | -log10(p-value) |
|---|---|
|
{{{tfbs_overrepresentation_jaspar}}} |
ENCODE TF ChIP-seq peak enrichment analysis<b>Summary:</b> For each TF and each co-expression cluster, the number of promoters with ENCODE TF ChIP signal was compared with the rest of promoters from the robust set using Fisher's exact test. Clusters with significant ChIP enrichment (q <= 0.05) after Benjamini-Hochberg correction were retained. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br><br>data
(#promoters = Number of promoters in this coexpression cluster that have ChIP signal of the TF)
| TF | #promoters | Enrichment | p-value | q-value |
|---|---|---|---|---|
| BCL11A#53335 | 6 | 17.0216730621642 | 3.55593058662976e-07 | 1.75592356755095e-05 |
| EBF1#1879 | 9 | 8.0158201619121 | 2.54528393136776e-08 | 1.77099872423796e-06 |
| ELF1#1997 | 9 | 3.83228816292678 | 1.71269377095518e-05 | 0.000392005313926775 |
| IRF4#3662 | 5 | 10.9572563433721 | 4.10495409675721e-05 | 0.000745724997236435 |
| MEF2A#4205 | 3 | 5.62296927289322 | 0.0137240387818804 | 0.0483251816028592 |
| NFKB1#4790 | 8 | 4.39045073935507 | 3.83990628335229e-05 | 0.000723630408385114 |
| PAX5#5079 | 7 | 4.66869587182448 | 0.000134123573520654 | 0.00175910233516559 |
| PBX3#5090 | 6 | 13.1487076120465 | 1.61405405165394e-06 | 6.12982513093401e-05 |
| POLR2A#5430 | 9 | 1.93270785890226 | 0.00598008918360611 | 0.0268106689953483 |
| POU2F2#5452 | 9 | 8.19551165196827 | 2.08994783441932e-08 | 1.48484395836e-06 |
| SP1#6667 | 8 | 4.55870510251272 | 2.88273233272976e-05 | 0.000603587975336736 |
| TAF1#6872 | 7 | 2.3401324000217 | 0.0104083984434833 | 0.038631178259318 |
| TBP#6908 | 8 | 2.96541654967711 | 0.000730287566864471 | 0.00581640381268653 |
| TCF12#6938 | 8 | 8.50757192174914 | 2.30735866354801e-07 | 1.21767676332638e-05 |
| YY1#7528 | 6 | 2.94670244991231 | 0.00698724787395188 | 0.0295370023762511 |
| ZEB1#6935 | 7 | 11.8219024122807 | 2.60652199876196e-07 | 1.34696957461009e-05 |
Relative expression of the co-expression cluster<b>Summary:</b>Co-expression clusters are compared against FANTOM5 samples to obtain relative expression. <br><b>Analyst:</b>NA<br><br>link to data source<br> data
This analysis result is provided for C0 - C305 clusters.
